ClinicalTrials.gg
RecruitingNCT06723236Updated Apr 27, 2026

A Study of MGC028 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of MGC028 in Advanced Solid Tumors, NSCLC Adenocarcinoma and Cholangiocarcinoma, sponsored by MacroGenics. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by MacroGenics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
124
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 109 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Planned enrollment
66th of 279
124 · median 44
Started
2025
with 16 others
Phase 1
85 of 328
14 open now
Primary completion
2026-11
later than 20 of 108 live
Registered
291st of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 66th largest by planned enrollment of the 279 interventional ones that give a count, is one of 17 that started in 2025, is one of 85 in phase 1, reaches primary completion later than 20 of the 108 other live ones, and was the 291st registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9.

The main question the study aims to answer is:

  • What types of side effects will participants experience when receiving MGC028?
  • Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors?

Participants will

  • Undergo screening procedures to determine eligibility
  • Receive study treatments initially every 3 weeks.
  • Have blood samples taken for routine and research tests
  • Have other examinations to check heart and lung function, and general health status
  • Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary.
  • Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.
03

Conditions studied

  • Advanced Solid Tumors
  • NSCLC Adenocarcinoma
  • Cholangiocarcinoma
  • Pancreatic Carcinoma
  • Colorectal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants in dose escalation or supplemental cohorts must have proven unresectable, locally advanced or solid tumor limited to one of the following types: NSCLC adenocarcinoma, cholangiocarcinoma, colorectal carcinoma (CRC), or pancreatic carcinoma that is to standard therapy, or for which standard therapy does not exist, has proven to be intolerable, or has been refused by the participant.
  • Participants in expansion cohorts must have either

    • NSCLC adenocarcinoma with

      • progression on or following /PD-L1 inhibitor, unless
      • progression on or following therapy for actionable mutations (e.g. EGFR or ALK mutations), if present
      • no more than 2 prior lines of cytotoxic chemotherapy for advanced or metastatic disease.
    • Pancreatic cancer

      • following at least 1 systemic therapy
      • no more than 2 prior lines of cytotoxic therapy for advanced or metastatic disease.
    • Colorectal adenocarcinoma with

      • Progression during or following standard therapy with a fluoropyrimidine-based chemotherapy, oxaliplatin and irinotecan unless contraindicated, refused or unavailable
      • Progression after prior targeted treatment for CRC with actionable mutations such as EGFR, KRAS, BRAF and MSI- H/dMMR, if present.
      • No more that 2 lines of cytotoxic chemotherapy for advanced or metastatic disease
      • No more than 4 lines of systemic regimens for advanced or metastatic disease
  • Participants must have at least one lesion that meets the definition of by v1.1.
  • Participants must have an available archival or formalin-fixed paraffin-embedded tumor tissue or be willing to undergo a procedure to obtain a fresh tumor sample.
  • Participants have acceptable physical condition and laboratory values.
  • Participants of must agree to use highly effective methods of .
  • Participants must not be pregnant, planning to be pregnant, or breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
  • Active or .
  • Prior stem cell, tissue, or solid organ transplant.
  • Another that required treatment within the past 2 years, with the exception of those with a negligible risk of or death such as adequately treated non-melanomatous skin cancer, localized prostate cancer (Gleason Score \< 6), or carcinoma in situ.
  • Active viral, bacterial, or fungal infection
  • Prior treatment with ADAM9 targeted agent for cancer.
  • Prior treatment with major surgery, mediastinal or lung radiation, vaccination with , systemic cancer treatment, chimeric antigen receptor (CAR)-T cell therapy, or experimental treatment within 4 weeks of the start of study treatment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Dose level 1 of MGC028, IV

    Biological: MGC028

  • Experimental
    Cohort 2

    Dose level 2 of MGC028, IV

    Biological: MGC028

  • Experimental
    Cohort 3

    Dose level 3 of MGC028, IV

    Biological: MGC028

  • Experimental
    Cohort 4

    Dose level 4 of MGC028, IV

    Biological: MGC028

  • Experimental
    Cohort 5

    Dose level 5 of MGC028, IV

    Biological: MGC028

  • Experimental
    Cohort 6

    Dose level 6 of MGC028, IV

    Biological: MGC028

  • Experimental
    Expansion Cohort 1

    MTD or MAD of MGC028, IV

    Biological: MGC028

  • Experimental
    Expansion Cohort 2

    MTD or MAD of MGC028, IV

    Biological: MGC028

  • Experimental
    Expansion Cohort 3

    MTD or MAD of MGC028, IV

    Biological: MGC028

Interventions

  • BiologicalMGC028

    MGC028 is an antibody-drug conjugate targeted against ADAM9.

06

What researchers measure

Primary outcomes

  1. Number and Types of Adverse Events (AEs) in Participants Receiving MGC028

    Types of AEs include Serious Adverse Events (SAEs), and AEs Leading to Treatment Delay or Discontinuation or Dose Reduction, dose limiting toxicities, and AEs of Special Interest. Observation of side effects determines the highest safe dose for further study

    Time frame: Throughout the study treatment and safety follow up period, up to 25 months

Secondary outcomes

  1. Mean maximum concentration of MGC028 antibody

    Measurement of the highest concentration of MGC028 conjugated and total antibody in the bloodstream.

    Time frame: Through Cycle 6 of the study, approximately 18 weeks

  2. Mean Area Under the Concentration Time Curve of MGC028 antibody

    Measurement of the total exposure of MGC028 conjugated and total antibody in the bloodstream.

    Time frame: Through Cycle 6 of the study, approximately 18 weeks

  3. Number of Participants Who Develop Anti-Drug Antibodies to MGC028

    Time frame: Throughout the study treatment period, up to 2 years

  4. Objective Response Rate (ORR)

    The ORR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is estimated as the proportion of participants in the Response Evaluable Population who achieve Best Overall Response of Complete Response or Partial Response.

    Time frame: Throughout the study and follow up period, up to 2.5 years.

  5. Median Duration of Response

    DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first.

    Time frame: Throughout the study and follow up period, up to 2.5 years.

  6. Mean maximum concentration of MGC028 free payload

    Measurement of the highest concentration of MGC028 free payload in the bloodstream.

    Time frame: Through Cycle 6 of the study, approximately 18 weeks

  7. Mean Area Under the Concentration Time Curve Total exposure of MGC028 payload

    Measurement of the total exposure of MGC028 free payload in the bloodstream

    Time frame: Through Cycle 6 of the study, approximately 18 weeks

  8. Change from baseline in the level of ADAM9 expression in tumor specimens, using immunohistochemistry

    Time frame: Baseline and approximately 28 days after the first dose of MGC028.

07

Study locations

7 of 7 sites recruiting
  • UCSF - Helen Diller Family Cancer Center
    San Francisco, California 94115, United States
    Recruiting
    • Pamela Munster · Principal investigator
  • Mass General Brigham
    Boston, Massachusetts 02114, United States
    Recruiting
    • Harshaband Singh · Principal investigator
  • Dana Farber/Harvard Cancer Center
    Boston, Massachusetts 02115, United States
    Recruiting
    • Kimberly Perez · Principal investigator
  • South Texas Accelerated Research Therapeutics (START) Midwest
    Grand Rapids, Michigan 49546, United States
    Recruiting
    • Manish Sharma · Principal investigator
  • Icahn School of Medicine at Mt. Sinai
    New York, New York 10029, United States
    Recruiting
    • Deborah Doroshow · Principal investigator
  • South Texas Accelerated Research Therapeutics (START) San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Drew Rasco · Principal investigator
  • South Texas Accelerated Research Therapeutics (START) Mountain Region
    West Valley City, Utah 84119, United States
    Recruiting
    • Justin Call · Principal investigator
08

References and documents

Publications

  • Scribner JA, Brown JG, Son T, Jin L, McKenzie C, Nam V, Bush C, Quinonez D, Ford D, Tamura J, Gorlatov S, Summers A, Hav M, Li H, Sharma NK, Zhang X, Diedrich G, Butler S, Bonvini E, Loo D. Preclinical Development of MGC028, an ADAM9-Targeted, Glycan-Linked, Exatecan-Based Antibody-Drug Conjugate for the Treatment of Solid Cancers. Mol Cancer Ther. 2026 Apr 2;25(4):517-528. doi: 10.1158/1535-7163.MCT-25-0461. PubMed 41166694 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2026, 21 months after the start.

Of 44 industry-sponsored phase 1 interventional studies under Cholangiocarcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 60. This study's planned 21 months is below that.

Counting every sponsor, half of 67 studies reached it within 46 months; a quarter within 30 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 9, 2024
StartActual
Feb 13, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Apr 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06723236
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Feb 13, 2025
Primary completion
Nov 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Apr 27, 2026

Study contacts

Global Trial Manager
Contact
info@macrogenics.com
301-251-5172
Pepi Pencheva, M.D.
study director · MacroGenics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion